A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)

被引:96
|
作者
Cross, Raymond K. [1 ]
Langenberg, Patricia [2 ]
Regueiro, Miguel [3 ]
Schwartz, David A. [4 ]
Tracy, J. Kathleen [2 ]
Collins, Joseph F. [2 ,5 ]
Katz, Jonathan [6 ]
Ghazi, Leyla [1 ]
Patil, Seema A. [1 ]
Quezada, Sandra M. [1 ]
Beaulieu, Dawn [4 ]
Horst, Sara N. [4 ]
Russman, Katharine [1 ]
Riaz, Mahrukh [1 ]
Jambaulikar, Guruprasad [1 ]
Sivasailam, Barathi [1 ]
Quinn, Charlene C. [2 ]
机构
[1] Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[3] Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA
[4] Vanderbilt Univ, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN USA
[5] Vet Affairs Cooperat Studies Program, Perry Point, MD USA
[6] CircleLink Hlth LLC, Norwalk, CT USA
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2019年 / 114卷 / 03期
基金
美国医疗保健研究与质量局;
关键词
QUALITY-OF-LIFE; ULCERATIVE-COLITIS; CROHNS-DISEASE; HOME TELEMANAGEMENT; SELF-MANAGEMENT; GASTROENTEROLOGY; NONADHERENCE; ACCEPTANCE; MEDICATION; INFLIXIMAB;
D O I
10.1038/s41395-018-0272-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION:Telemedicine has shown promise in inflammatory bowel disease (IBD). The objective of this study was to compare disease activity and quality of life (QoL) in a 1-year randomized trial of IBD patients receiving telemedicine vs. standard care.METHODS:Patients with worsening symptoms in the prior 2 years were eligible for randomization to telemedicine (monitoring via texts EOW or weekly) or standard care. The primary outcomes were the differences in change in disease activity and QoL between the groups; change in healthcare utilization among groups was a secondary aim.RESULTS:348 participants were enrolled (117 control group, 115 TELE-IBD EOW, and 116 TELE-IBD weekly). 259 (74.4%) completed the study. Age was 38.9 12.3 years, 56.6% were women, 91.9% were Caucasian, 67.9% had Crohn's disease (CD) and 42.5% had active disease at baseline. In CD, all groups experienced a decrease in disease activity (control -5.2 +/- 5.0 to 3.7 +/- 3.6, TELE-IBD EOW 4.7 +/- 4.1 to 4.2 +/- 3.9, and TELE-IBD weekly 4.2 +/- 4.2 to 3.2 +/- 3.4, p < 0.0001 for each of the groups) In UC, only controls had a significant decrease in disease activity (control 2.9 +/- 3.1 to 1.4 +/- 1.4, p = 0.01, TELE-IBD EOW 2.7 +/- 3.1 to 1.7 +/- 1.9, p = 0.35, and TELE-IBD Weekly 2.5 +/- 2.5 to 2.0 +/- 1.8, p = 0.31). QoL increased in all groups; the increase was significant only in TELE-IBD EOW (control 168.1 +/- 34.0 to 179.3 +/- 28.2, p = 0.06, TELE-IBD EOW 172.3 +/- 33.1 to 181.5 +/- 28.2, p = 0.03, and TELE-IBD Weekly 172.3 +/- 34.5 to 179.2 +/- 32.8, p = 0.10). Unadjusted and adjusted changes in disease activity and QoL were not significantly different among groups. Healthcare utilization increased in all groups. TELE-IBD weekly were less likely to have IBD-related hospitalizations and more likely to have non-invasive diagnostic tests and electronic encounters compared to controls; both TELE-IBD groups had decreased non-IBD related hospitalizations and increased telephone calls compared to controls.DISCUSSION:Disease activity and QoL, although improved in all participants, were not improved further through use of the TELE-IBD system. TELE-IBD participants experienced a decrease in hospitalizations with an associated increase in non-invasive diagnostic tests, telephone calls and electronic encounters. Research is needed to determine if TELE-IBD can be improved through patient engagement and whether it can decrease healthcare utilization by replacing standard care.
引用
收藏
页码:472 / 482
页数:11
相关论文
共 50 条
  • [1] A RANDOMIZED CONTROLLED TRIAL OF TELEMEDICINE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (TELE-IBD)
    Cross, Raymond K.
    Langenberg, Patricia
    Regueiro, Miguel D.
    Schwartz, David A.
    Tracy, J. K.
    Collins, Joseph
    Katz, Jonathan
    Ghazi, Leyla
    Patil, Seema
    Quezada, Sandra M.
    Russman, Katharine M.
    Riaz, Mahrukh
    Jambaulikar, Guruprasad
    Sivasailam, Barathi
    Quinn, Charlene C.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S177 - S177
  • [2] TELEMEDICINE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (TELE-IBD)
    Cross, Raymond K.
    Quinn, Charlene C.
    Russman, Katharine
    Regueiro, Miguel D.
    Ghazi, Leyla J.
    Schwartz, David A.
    Patil, Seema
    Quezada, Sandra M.
    Horst, Sara N.
    Beaulieu, Dawn
    Tracy, J. K.
    Jambaulikar, Guruprasad
    Langenberg, Pat
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S596 - S596
  • [3] TELEmedicine for Patients With Inflammatory Bowel Disease (TELE-IBD)
    Jambaulikar, Guruprasad
    Langenberg, Patricia
    Katz, Jonathan
    Quinn, Charlene
    Flasar, Mark
    Regueiro, Miguel
    Ghazi, Leyla
    Patil, Seema
    Schwartz, David
    Cross, Ray
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S521 - S521
  • [4] TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial
    Cross, Raymond K.
    Jambaulikar, Guruprasad
    Langenberg, Patricia
    Tracy, J. Kathleen
    Collins, Joseph F.
    Katz, Jonathan
    Regueiro, Miguel
    Schwartz, David A.
    Quinn, Charlene C.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2015, 42 : 132 - 144
  • [5] TELEmedicine for Patients With Inflammatory Bowel Disease (TELE-IBD): A Qualitative Assessment
    Roth, Erin
    Chard, Sarah
    Eckert, J. Kevin
    Cross, Ray, Jr.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S375 - S375
  • [6] TELEMEDICINE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (TELE-IBD) DECREASES INFLAMMATORY BOWEL DISEASE (IBD)-RELATED HOSPITALIZATIONS
    Sivasailam, Barathi
    Cross, Raymond K.
    Ghazi, Leyla
    Patil, Seema A.
    Quezada, Sandra M.
    Russman, Katharine
    Riaz, Mahrukh
    Jambaulikar, Guruprasad
    Quinn, Charlene C.
    Langenberg, Patricia
    Tracy, J. Kathleen
    Regueiro, Joseph F. Collins Miguel
    Schwartz, David A.
    Katz, Jonathan
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S60 - S61
  • [7] TELEMEDICINE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (TELE-IBD) DECREASES INFLAMMATORY BOWEL DISEASE (IBD)-RELATED HOSPITALIZATIONS
    Sivasailam, Barathi
    Cross, Raymond K.
    Ghazi, Leyla
    Patil, Seema A.
    Quezada, Sandra M.
    Russman, Katharine
    Riaz, Mahrukh
    Jambaulikar, Guruprasad
    Quinn, Charlene C.
    Langenberg, Patricia
    Tracy, J. Kathleen
    Regueiro, Joseph F. Collins Miguel
    Schwartz, David A.
    Katz, Jonathan
    [J]. GASTROENTEROLOGY, 2018, 154 (01) : S86 - S87
  • [8] The Telemedicine for Patients With Inflammatory Bowel Disease (TELE-IBD) Clinical Trial: Qualitative Assessment of Participant's Perceptions
    Quinn, Charlene Connolly
    Chard, Sarah
    Roth, Erin G.
    Eckert, J. Kevin
    Russman, Katharine M.
    Cross, Raymond K.
    [J]. JOURNAL OF MEDICAL INTERNET RESEARCH, 2019, 21 (06)
  • [9] Demographic and Clinical Predictors of Adherence to Self-testing in Telemedicine for Patients With Inflammatory Bowel Disease (TELE-IBD)
    Chudy-Onwugaje, Kenechukwu
    Langenberg, Patricia
    Regueiro, Miguel
    Schwartz, David A.
    Tracy, J. Kathleen
    Katz, Jonathan
    Ghazi, Leyla
    Patil, Seema
    Quezada, Sandra M.
    Russman, Katharine
    Quinn, Charlene
    Cross, Raymond K., Jr.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S347 - S349
  • [10] EFFECT OF TELEMEDICINE FOR INFLAMMATORY BOWEL DISEASE (TELE-IBD) ON PATIENT ACTIVATION AND GENERAL SELF-EFFICACY
    Bilgrami, Zaid
    Abutaleb, Ameer
    Chudy-Onwugaje, Kenechukwu
    Cross, Raymond
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S1109 - S1110